Analysts HC Wainwright and Wedbush maintain "Buy" and "Outperform" ratings for Gossamer Bio, setting price targets at $10 and $6, respectively.

HC Wainwright has reiterated its "Buy" rating for Gossamer Bio (NASDAQ:GOSS) and set a $10.00 price target, while Wedbush also reiterated an "Outperform" rating and set a $6.00 price target. Gossamer Bio's estimated earnings for Q1 2024 are ($0.15) EPS, with FY2024 earnings at ($0.61) EPS and a consensus target price of $5.35. The company has a 1-year low of $0.45 and a 1-year high of $1.88.